Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/13708
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Patarica-Huber E. | en |
dc.contributor.author | Boškov, Novak | en |
dc.contributor.author | Pjevic M. | en |
dc.date.accessioned | 2020-03-03T14:53:25Z | - |
dc.date.available | 2020-03-03T14:53:25Z | - |
dc.date.issued | 2011-01-01 | en |
dc.identifier.issn | 11070625 | en |
dc.identifier.uri | https://open.uns.ac.rs/handle/123456789/13708 | - |
dc.description.abstract | Purpose: This study evaluated the effects of the multimodal therapy (gabapentin-non steroidal anti inflammatory drug [NSAID]-morphine) on intensity and relief of treatment-related neuropathic pain inpatients with breast cancer. Methods: This study involved 75 breast cancer outpatients who had previously undergone anti-neoplastic therapy (surgery, chemotherapy, radiotherapy). The patients were randomly divided into 3 groups, which were formed depending on the planned analgesic therapy (gabapentin, gabapentin-NSAID, gabapentin-NSAID- morphine). Each group was a control group to itself. The pain intensity difference and scores of daily activities were collated and assessed by the modified Brief Pain Inventory (BPI) questionnaire (VAS/Likert Scale). Monitoring the additional medication and side effects optimized the therapy efficiency evaluation. Results: During this 6-week study, the decrease of pain intensity was significant in all 3 groups (p <0.0001). Although there was intergroup difference, it was statistically not significant (p >0.05). The variant analysis of pain relief showed differences both among and within the groups in thefirst 3 weeks of the study (F1=7.79, p=0.000; F2=7.01, p=0.001; F3=5.49, p=0.001). The multimodal group needed the least of additional medication and the variant analysis showed a statistically significant difference (p=0.001) from the 4th week of the trial period. The correlation between the increase trend of side effects and the frequency of additional medication was significant (p <0.05). Conclusion: The multimodal therapy ensures adequate cancer-related neuropathic pain control with minimal side effects. © 2011 Zerbinis Medical Publications. | en |
dc.relation.ispartof | Journal of B.U.ON. | en |
dc.title | Multimodal approach to therapy-related neuropathic pain in breast cancer | en |
dc.type | Journal/Magazine Article | en |
dc.identifier.pmid | 16 | en |
dc.identifier.scopus | 2-s2.0-79954503233 | en |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/79954503233 | en |
dc.relation.lastpage | 45 | en |
dc.relation.firstpage | 40 | en |
dc.relation.issue | 1 | en |
dc.relation.volume | 16 | en |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Fakultet tehničkih nauka, Departman za računarstvo i automatiku | - |
crisitem.author.parentorg | Fakultet tehničkih nauka | - |
Appears in Collections: | FTN Publikacije/Publications |
SCOPUSTM
Citations
17
checked on May 10, 2024
Page view(s)
28
Last Week
10
10
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.